PHARMA

PHARMA

Pharmaceutical Hydrogenation Membrane in Taiwan

Catalytic hydrogenation is a critical step in active pharmaceutical ingredient (API) synthesis. Taiwan's semiconductor manufacturing sector is a significant consumer of ultra-pure hydrogen, while the island's net-zero pathway includes green hydrogen for industrial decarbonization.

Market Context

Taiwan

Policy

Taiwan 2050 Net Zero Emissions Pathway

H₂ Target

Hydrogen integration in industrial decarbonization

2

Cities

3

Industries

Ultra-Clean Hydrogen Source

Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.

GMP-Compatible On-Site Generation

On-site electrolysis provides a controlled, traceable hydrogen source that simplifies GMP documentation and qualification versus multi-sourced delivered gas.

Batch-Flexible Operation

Pharmaceutical manufacturing operates in batches. IONZERA's high wettability supports start-stop operation, generating hydrogen only when hydrogenation reactors require it.

Pharmaceutical Hydrogenation in Taiwan’s Hydrogen Market

Taiwan's semiconductor manufacturing sector is a significant consumer of ultra-pure hydrogen, while the island's net-zero pathway includes green hydrogen for industrial decarbonization. Offshore wind development around Kaohsiung creates opportunities for wind-to-hydrogen projects.

IONZERA supports Taiwan's dual hydrogen needs: ultra-pure H2 for semiconductor fabs via on-site electrolysis, and green hydrogen for industrial decarbonization.

Semiconductor ManufacturingOffshore Wind-to-H2Petrochemicals
3x

Lower Resistance

20%

Thinner Profile

PERFORMANCE ADVANTAGE

Why IONZERA for Pharmaceutical Hydrogenation in Taiwan

Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.

Shipping & Logistics

Air freight from India to Taipei in 4-5 business days.

Area Resistance

3x LOWER
Area Specific Resistance ComparisonIONZERA0.09-0.1 Ω·cm²Zirfon0.30 Ω·cm²00.10.20.3 Ω·cm²~3x Lower

Thickness

20% THINNER
Membrane Thickness ComparisonIONZERA350-410 μmZirfon500 μm500 μm scale20-30%thinnerThinner membrane = More compact stacks= Higher power density

Pharmaceutical Hydrogenation Membrane in Taiwan Cities

Frequently Asked Questions

Why choose IONZERA for pharmaceutical hydrogenation in Taiwan?

IONZERA delivers 3x lower ionic resistance than Zirfon, making it ideal for pharmaceutical hydrogenation applications in Taiwan. IONZERA supports Taiwan's dual hydrogen needs: ultra-pure H2 for semiconductor fabs via on-site electrolysis, and green hydrogen for industrial decarbonization.

Can IONZERA-based electrolysers produce semiconductor-grade hydrogen?

IONZERA membranes enable high-efficiency alkaline electrolysis with low gas crossover (<0.5% H2 in O2). When paired with appropriate purification stages, AWE systems using IONZERA can produce hydrogen suitable for semiconductor fabrication processes.

Ready to Start

Request Pharmaceutical Hydrogenation Samples for Taiwan

Contact G-Hexa for IONZERA pharmaceutical hydrogenation membrane samples, technical specifications, and volume pricing for Taiwan-based projects.

Request Sample